Skip to main content

Vaxcyte, Inc.

PCVX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001649094

In the last 90 days, Vaxcyte, Inc. insiders filed 0 open-market purchases and 8 sales; 331 institutions reported holding it in 13F filings for Q2 2026, worth $9.71B in total; Maverick Capital is the only superinvestor holding it.

Q2 2021 vs. Q1 2021

How the institutions holding Vaxcyte, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of PCVX: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders7475+1
Shares44.0M43.2M−799.5K (−1.8%)
Value$869.2M$972.7M+$103.6M (+11.9%)

New holders (12)

Institutions that held Vaxcyte, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to PCVX in Q2 2021
InstitutionSharesValue% of portfolio
Ghost Tree Capital, LLC145,000$3.26M1.02%
Employees Retirement System of Texas58,441$1.32M0.02%
Parametric Portfolio Associates LLC25,978$585.0K0.00%
Susquehanna International Group, LLP18,936$426.0K0.00%
Squarepoint Ops LLC16,504$372.0K0.00%
Invesco Ltd.14,563$328.0K0.00%
State Board of Administration of Florida Retirement System12,691$286.0K0.00%
Price T Rowe Associates Inc10,339$233.0K0.00%
Macquarie Group Ltd1,992$45.0K0.00%
Quantbot Technologies LP1,500$33.0K0.00%
O'Shaughnessy Asset Management, LLC426$10.0K0.00%
Lindbrook Capital, LLC17$00.00%

Sold out (11)

Institutions that held Vaxcyte, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.